Fuad El-Hibri Blog

Fuad El-Hibri’s Emergent BioSolutions’ Typhoid Vaccine | June 15, 2009

Fuad El-Hibri’s Emergent BioSolutions‘ Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study

“We are very pleased to have met the objectives of this Phase II study of our typhoid vaccine candidate. This data is encouraging and indicates great promise for what would be the first single-dose, drinkable typhoid vaccine. We are particularly grateful to the Wellcome Trust for their partnership and generous support of this important project,” stated Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “Typhoid is endemic in many developing countries, putting countless international travelers and families who visit these nations at risk. With typhoid claiming 200,000 lives each year, continued progress in the development of this vaccine is an important milestone in our company’s efforts to protect life. Emergent BioSolutions remains committed to addressing significant underserved health needs,” he continued.

About the Typhoid Vaccine Candidate

The company’s typhoid vaccine candidate is a live, attenuated strain of the Salmonella typhi bacterium designed to eliminate virulence by deletion of two specific genes. The vaccine is intended to be administered in a single, drinkable dose prior to travel to countries where typhoid is endemic. If approved, this method of administration could provide a competitive advantage compared to currently approved typhoid vaccines.

Reblog this post [with Zemanta]
Posted in El-Hibri Fuad, Emergent, Emergent BioSolutions, Emergent BioSolutions Inc, Ernst & Young, Ernst & Young Entrepreneur of the Year, Fuad El-Hibri, Typhoid Vaccine
Tags: , , , , , , ,

1 Comment

  1. [...] Fuad El-Hibri’s Emergent BioSolutions’ Typhoid Vaccine Jun 15 Comments [...]

    Pingback by Fuad El-Hibri and EBS Trading | Fuad El-Hibri Online — June 17, 2009 @ 2:57 am


Sorry, the comment form is closed at this time.

About author

Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax disease. The company is also investing heavily in the development of a broad pipeline of products that address specific global unmet medical needs, including Typhoid, Tuberculosis, Hepatitis B and Chlamydia. Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. (Porton), a mid-sized biotechnology company in the United Kingdom. Subsequent to the successful marketing and distribution of Porton’s biodefense vaccines to foreign governments in the early 1990’s, Mr. El-Hibri organized a management buyout of Porton in 1994, forming Speywood Holdings, Ltd. He was appointed to the Board of Directors of Speywood Holdings, Ltd. and acted as an advisor to the senior management team in the operations of the company until 1996. Starting in the 1990’s, Mr. El-hibri formed and then sold three mobile telecommunications companies, Mobile TeleSystems, serving the greater Moscow region, as well as Digitel and Digicel, serving markets in South and Central America. Mr. El-Hibri began his career with Citigroup in commercial banking and subsequently in mergers & acquisitions. Following his tenure at Citigroup, Mr. El-Hibri joined Booz Allen & Hamilton as a management consultant in South East Asia, where he led several large client engagements.

Search

Navigation

Categories:

Links:

Archives:

Feeds